QuidelOrtho Corp (QDEL) stock
QDELNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends January 1
Financials through Q3 FY2026, quarter ended Sep 27, 2026Last filing: 10-Q on Nov 4, 2026Score 6/3063% below fair value
$9.87−0.34 (-3.33%)
Close on Nov 17, 2026Market cap $676.84MP/E –Yield –
QuidelOrtho r&d expenses
Research and development expenses are spending on new products and technology.
QuidelOrtho's R&D Expenses for the twelve months ending Sep 27, 2026 was $181.90M, down 3.1% year over year. For fiscal 2025 it was $186.20M, down 14.9% from the year before. The highest annual figure on record is $245.00M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $186.20M | -14.9% |
| FY2024 | Dec 29, 2024 | $218.70M | -10.7% |
| FY2023 | Dec 31, 2023 | $245.00M | +30.4% |
| FY2022 | Jan 1, 2023 | $187.90M | +96.3% |
| FY2021 | Jan 2, 2022 | $95.70M | +13.5% |
| FY2020 | Jan 3, 2021 | $84.30M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 27, 2026 | $42.50M | +2.4% |
| Q2 FY2026 | Jun 28, 2026 | $48.70M | +6.6% |
| Q1 FY2026 | Mar 29, 2026 | $44.90M | -15.6% |
| Q4 FY2025 | Dec 28, 2025 | $45.80M | -3.2% |
| Q3 FY2025 | Sep 28, 2025 | $41.50M | -25.8% |
| Q2 FY2025 | Jun 29, 2025 | $45.70M | -18.8% |
| Q1 FY2025 | Mar 30, 2025 | $53.20M | -10.1% |
| Q4 FY2024 | Dec 29, 2024 | $47.30M | -20.2% |
| Q3 FY2024 | Sep 29, 2024 | $55.90M | -9.1% |
| Q2 FY2024 | Jun 30, 2024 | $56.30M | -9.8% |
| Q1 FY2024 | Mar 31, 2024 | $59.20M | -5.0% |
| Q4 FY2023 | Dec 31, 2023 | $59.30M | -3.9% |
| Q3 FY2023 | Oct 1, 2023 | $61.50M | -6.3% |
| Q2 FY2023 | Jul 2, 2023 | $62.40M | +82.5% |
| Q1 FY2023 | Apr 2, 2023 | $62.30M | +136.0% |
| Q4 FY2022 | Jan 1, 2023 | $61.70M | +136.4% |
| Q3 FY2022 | Oct 2, 2022 | $65.60M | +176.8% |
| Q2 FY2022 | Jul 3, 2022 | $34.20M | +51.3% |
| Q1 FY2022 | Apr 3, 2022 | $26.40M | – |
| Q4 FY2021 | Jan 2, 2022 | $26.10M | – |
| Q3 FY2021 | Oct 3, 2021 | $23.70M | – |
| Q2 FY2021 | Jul 4, 2021 | $22.60M | – |
See a number that looks wrong?